MX2024005670A - Analogos deuterados de acetil-leucina. - Google Patents
Analogos deuterados de acetil-leucina.Info
- Publication number
- MX2024005670A MX2024005670A MX2024005670A MX2024005670A MX2024005670A MX 2024005670 A MX2024005670 A MX 2024005670A MX 2024005670 A MX2024005670 A MX 2024005670A MX 2024005670 A MX2024005670 A MX 2024005670A MX 2024005670 A MX2024005670 A MX 2024005670A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- formula
- treating
- present disclosure
- provides compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción proporciona compuestos representados por la Fórmula I, y las sales y solvatos farmacéuticamente aceptables de los mismos, en donde R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, y R13 son como se definen en la especificación, y el enriquecimiento con deuterio de cualquiera de uno o más de R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, y R13 es aproximadamente 15% o más. La presente descripción también proporciona compuestos que tienen la Fórmula I para su uso para tratar o retrasar la progresión de un trastorno de almacenamiento lisosómico o una enfermedad neurodegenerativa en un sujeto, proporcionar neuroprotección en un sujeto que tiene un trastorno lisosómico, tratar o prevenir migraña y síntomas asociados con el mismo, en un sujeto, o mejorar la movilidad y/o función cognitiva en un sujeto. (ver Fórmula).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776297P | 2018-12-06 | 2018-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005670A true MX2024005670A (es) | 2024-05-30 |
Family
ID=68887086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006559A MX2021006559A (es) | 2018-12-06 | 2019-12-06 | Analogos deuterados de acetil-leucina. |
| MX2024005670A MX2024005670A (es) | 2018-12-06 | 2021-06-03 | Analogos deuterados de acetil-leucina. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006559A MX2021006559A (es) | 2018-12-06 | 2019-12-06 | Analogos deuterados de acetil-leucina. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12145899B2 (es) |
| EP (1) | EP3886986A1 (es) |
| JP (2) | JP7471298B2 (es) |
| KR (2) | KR102765448B1 (es) |
| CN (2) | CN120157593A (es) |
| AU (1) | AU2019391434B2 (es) |
| BR (1) | BR112021010923A2 (es) |
| IL (2) | IL319687A (es) |
| MA (1) | MA54289A (es) |
| MX (2) | MX2021006559A (es) |
| SA (1) | SA521422185B1 (es) |
| SG (1) | SG11202106009TA (es) |
| WO (1) | WO2020115715A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| IL319687A (en) | 2018-12-06 | 2025-05-01 | Intrabio Ltd | Deuterated acetyl-leucine analogs |
| WO2022264037A1 (en) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Branched-chain amino acid derivatives to treat disease |
| US12403111B2 (en) | 2024-02-02 | 2025-09-02 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1087725C (zh) * | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| US20060063827A1 (en) | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| CN103188933A (zh) * | 2010-10-26 | 2013-07-03 | 泰华制药工业有限公司 | 富集氘的雷沙吉兰 |
| MX370884B (es) | 2013-02-05 | 2020-01-09 | Teva Pharmaceuticals Int Gmbh | Derivados de catecolamina enriquecidos con deuterio asimétrico posición-específico y medicamentos que comprenden los compuestos. |
| US10905670B2 (en) * | 2016-04-19 | 2021-02-02 | Intrabio Ltd. | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| MA55947A (fr) * | 2016-08-11 | 2022-03-23 | Intrabio Ltd | Compositions pharmaceutiques et utilisations dirigées vers des troubles d'entreposage lysosomial |
| HRP20191055T1 (hr) | 2016-08-11 | 2019-09-06 | Intrabio Ltd | Terapeutska sredstva za neurodegenerativne bolesti |
| PT3600276T (pt) | 2017-03-28 | 2023-07-11 | Intrabio Ltd | Beta-histina, ou um seu sal farmaceuticamente aceitável, e um inibidor da monoamina oxidase, para utilização no tratamento ou prevenção de um ou mais sintomas de vertigem num indivíduo |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| EP3697406A1 (en) | 2017-10-18 | 2020-08-26 | IntraBio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
| PT3752141T (pt) | 2018-02-15 | 2024-07-11 | Intrabio Ltd | Acetil-leucina para utilizaçâo no tratamento do síndrome das pernas inquietas |
| IL319687A (en) | 2018-12-06 | 2025-05-01 | Intrabio Ltd | Deuterated acetyl-leucine analogs |
| US10950670B2 (en) * | 2018-12-17 | 2021-03-16 | Wuhan China Star Optoelectronics Semiconductor Display Technology Co., Ltd. | Display panel |
| EP3934637B1 (en) * | 2019-03-02 | 2024-07-31 | IntraBio Ltd | (n-)acetyl-l-leucine for use in treating traumatic brain injury |
| DK3989962T3 (da) | 2019-06-28 | 2025-10-13 | Intrabio Ltd | Kombinationsterapi med acetyl-leucin og miglustat til behandling af en lysosomal lagringssygdom |
| US20230051742A1 (en) * | 2020-01-13 | 2023-02-16 | Intrabio Ltd. | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
| MX2022014466A (es) * | 2020-05-22 | 2022-12-13 | Intrabio Ltd | Combinacion de acetil leucina y 4-aminopiridina o acetazolamida para tratar la ataxia. |
-
2019
- 2019-12-06 IL IL319687A patent/IL319687A/en unknown
- 2019-12-06 SG SG11202106009TA patent/SG11202106009TA/en unknown
- 2019-12-06 IL IL283673A patent/IL283673B2/en unknown
- 2019-12-06 AU AU2019391434A patent/AU2019391434B2/en active Active
- 2019-12-06 MX MX2021006559A patent/MX2021006559A/es unknown
- 2019-12-06 BR BR112021010923-4A patent/BR112021010923A2/pt unknown
- 2019-12-06 KR KR1020217019782A patent/KR102765448B1/ko active Active
- 2019-12-06 JP JP2021531964A patent/JP7471298B2/ja active Active
- 2019-12-06 WO PCT/IB2019/060525 patent/WO2020115715A1/en not_active Ceased
- 2019-12-06 MA MA054289A patent/MA54289A/fr unknown
- 2019-12-06 CN CN202510303881.2A patent/CN120157593A/zh active Pending
- 2019-12-06 KR KR1020257003486A patent/KR20250022899A/ko active Pending
- 2019-12-06 US US17/311,240 patent/US12145899B2/en active Active
- 2019-12-06 EP EP19820881.1A patent/EP3886986A1/en active Pending
- 2019-12-06 CN CN201980090399.8A patent/CN113348018B/zh active Active
-
2021
- 2021-06-03 MX MX2024005670A patent/MX2024005670A/es unknown
- 2021-06-06 SA SA521422185A patent/SA521422185B1/ar unknown
-
2024
- 2024-04-09 JP JP2024062686A patent/JP2024095769A/ja not_active Withdrawn
- 2024-10-21 US US18/921,779 patent/US20250129011A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL283673A (en) | 2021-07-29 |
| JP2022514823A (ja) | 2022-02-16 |
| AU2019391434A1 (en) | 2021-07-08 |
| US20220024858A1 (en) | 2022-01-27 |
| CN113348018A (zh) | 2021-09-03 |
| IL283673B1 (en) | 2025-04-01 |
| KR20210111757A (ko) | 2021-09-13 |
| SG11202106009TA (en) | 2021-07-29 |
| MA54289A (fr) | 2021-10-06 |
| JP7471298B2 (ja) | 2024-04-19 |
| CA3122223A1 (en) | 2020-06-11 |
| AU2019391434B2 (en) | 2025-01-09 |
| CN120157593A (zh) | 2025-06-17 |
| EP3886986A1 (en) | 2021-10-06 |
| IL319687A (en) | 2025-05-01 |
| WO2020115715A1 (en) | 2020-06-11 |
| US20250129011A1 (en) | 2025-04-24 |
| MX2021006559A (es) | 2021-08-16 |
| IL283673B2 (en) | 2025-08-01 |
| KR102765448B1 (ko) | 2025-02-07 |
| JP2024095769A (ja) | 2024-07-10 |
| SA521422185B1 (ar) | 2024-04-24 |
| CN113348018B (zh) | 2025-04-01 |
| BR112021010923A2 (pt) | 2021-08-24 |
| US12145899B2 (en) | 2024-11-19 |
| KR20250022899A (ko) | 2025-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005670A (es) | Analogos deuterados de acetil-leucina. | |
| MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
| CL2016001287A1 (es) | Benzamidas sustituidas y procedimiento para su uso | |
| MX2020007485A (es) | Compuestos antiproliferativos y metodos de uso de los mismos. | |
| ES2770058T3 (es) | Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante | |
| MX2020000261A (es) | Nuevos compuestos. | |
| CO7160015A2 (es) | Benzamidas n-sustituidas y su uso en el tratamiento del dolor | |
| AR100154A1 (es) | Compuesto heterocíclico que contiene nitrógeno | |
| CL2017002452A1 (es) | Nuevos compuestos bicíclicos | |
| ES2620379T3 (es) | Quinolina y quinoxalina amidas como moduladores de canales de sodio | |
| AR095823A1 (es) | Compuesto de ciclopropanamina y uso del mismo | |
| CR20170118A (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| MX2019015888A (es) | Bifenil amidas con grupos eter modificados como inhibidores de hsp90 e inductores de hsp70. | |
| AR094277A1 (es) | Derivados de fumarato sustituidos con deuterio | |
| UY32483A (es) | Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| CL2019002919A1 (es) | Compuestos inhibidores vmat2 y composiciones relacionadas. | |
| MX2019003724A (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| MA40281B1 (fr) | Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
| MX377172B (es) | Formulacion de combinacion de tesofensina y betabloqueante | |
| MX385276B (es) | Tratamiento para la enfermedad de parkinson | |
| MX2019003310A (es) | Inhibidores de dopamina-b-hidroxilasa. |